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Abstract
In this communication we describe a novel way to use Next Generation Sequence from the 
receptors expressed on T and B cells. This informatics methodology is named iWAS, for 
immunonome Wide Association Study, where we use the immune receptor sequences derived 
from T and B cells and the features of those receptors (sequences themselves, V/J gene usage, 
length and character each of the CDR3 sub-regions) to define biomarkers of health and disease, as 
well as responses to therapies. Unlike GWAS, which do not provide immediate access to 
mechanism, the associations with immune receptors immediately suggest possible and plausible 
entrée's into disease pathogenesis and treatment.
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1. Introduction
Immunological tolerance is one of the key characteristics of adaptive immunity. The 
mammalian immune system has the ability to differentiate between self and foreign agents, 
by tolerating the presence of antigens from self and commensal microbes, while responding 
robustly to foreign antigens. It has been 70 years since Ray Owen's seminal observation in 
dizygotic cows that led to the development of the concept of tolerance [1]. The subsequent 7 
decades of work on lymphocyte development, antigen processing/presentation, thymic 
regulation and peripheral tolerance mechanisms have shed light on the machinery 
responsible for establishing tolerance [1,2]. It is clear that lymphocyte deletion, lymphocyte 
anergy, and lymphocyte repression are central to the development of self tolerance by 
establishment of a tolerant adaptive immune receptor repertoire.
While we know much about WHERE and HOW lymphocytes are selected and enter the 
circulating repertoire, we know precious little about WHICH lymphocytes are selected in the 
process of developing tolerance. The challenge is identifying the characteristics of adaptive 
immune receptor sequences that increase or decrease the likelihood of selection. The main 
limitation in identifying which T cells and B cells are modulated (deleted, anergized or 
repressed) during tolerance is the sheer magnitude of the potential repertoire of variation that 
is possible in the species of T cell receptors (TCR) and B cell receptor (BCR=antibodies) as 
well as their partially non-germline encoded character. Initially, the sequencing of immune 
receptors was only possible in small numbers that were insufficient to find patterns in the 
tolerance process. A clear example of the under-sampling of the pre- and post-selection 
thymic repertoire utilizing classical sequencing techniques is highlighted in research from 
the Mathis lab [3]. In this work, over 600 TCR sequences were analyzed in an intensive 
sequencing effort to characterize the repertoire changes that occur during central tolerance in 
the thymus. In spite of this effort, it is clear that the thymic repertoire was under-sampled 
and the main conclusions from the manuscript were restricted to observations of skewed J-
beta gene usage for selected V-gene bearing TCRs. Ten years after that study, a novel 
strategy to overcome this sampling conundrum was developed by the same group, wherein a 
TCR α minilocus transgenic mouse with limited diversity in the alpha chain locus was 
utilized to assess the changes in TCR repertoire during central tolerance [4]. In spite 
sequencing many hundreds of TCRs, the authors came to the conclusion that class I and II 
restricted clones differ but “no overriding rule emerges, and minute sequence differences 
can switch MHC class preference”. However, with the advent of high throughput 
sequencing technologies, this sampling limitation has been essentially circumvented. Pre-
selection and post-selection repertoires can now be readily assessed at sufficient coverage to 
allow the interrogation of the selection process to, in essence, identify the cellular 
clonotypes that are deleted, anergized or repressed upon tolerance induction.
A remaining challenge is the ability to informatically mine such datasets for those critical 
immune receptors that are involved in the tolerance process. Inspired by the computations 
utilized in Genome Wide Association Studies (GWAS), we propose an algorithm that we 
now term an immunome Wide Association Study (iWAS) to mine immune repertoire for 
immune receptor sequences that correlate with immunological phenotypes (e.g. including 
but not limited to the development of tolerance).
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1.1 History of Immune Tolerance Genetics
The idea of using genetic approaches to interrogate the status of the immune system in 
health and disease is not new. In the 1960s, data in mice showed that genetics could control 
immune responses. Biozzi successfully selected two strains of mice from an outbred colony 
for high and low antibody responses to sheep erythrocytes, demonstrating that differences in 
adaptive immune responses were characteristic of a particular genotype and thus under the 
control of genetic regulation [5]. Benacerraf and colleagues were then able to identify 
guinea pigs that were high and low responders to synthetic polypeptides, and that the Major 
Histocompatibility Complex (MHC) controlled this response [6,7]. This research was 
quickly extended to mice where more refined genetic tools solidified the result. It became 
clear that genetic regulation of the adaptive immune response was generalizable and genetic 
regulation could be mapped to specific gene loci. These seminal studies, along with the need 
for histocompatibility matching in transplantation, drove the characterization of the MHC. 
Skin transplantation in humans and other outbred species demonstrated that nearly all 
unrelated individuals rejected skin grafts. This was the first evidence that the MHC was 
highly polymorphic. The following years demonstrated that the MHC was perhaps the most 
polymorphic region of the mouse and human genome [8], with more than 12,000 alleles of 
human class I and II genes identified to date [9]. This extensive polymorphism created a tool 
for examining the association of the immune response and a disease susceptibility or 
resistance phenotype. Thus, the MHC locus proved useful as a marker for association 
studies, to allow for the examination of the correlation of a particular allele or alleles with a 
particular disease state [10-12]. The best known of these include the striking association of 
HLA-B27 family alleles with ankylosing spondylitis (AS). The relative risk for developing 
AS is nearly 100 fold higher in HLA-B27+ individuals compared to the general population. 
Important susceptibility and protective associations have also been found. In Type 1 
Diabetes there are both disease associated and protective alleles. DR3 and DR4 individuals 
have increased risk for developing Type I Diabetes and in DR3/DR4 heterozygotes the risk 
is further increased [13]. In contrast, DR2 individuals are protected from developing Type 1 
Diabetes [14]. Thus, the concept of using immune markers in disease association is well 
established. While there are many studies examining the genetics of host resistance, the 
allele phenotypes tend to be simple and the polymorphism not extensive.
The most heavily investigated alleles in the MHC locus, Class I and Class II, are associated 
with antigen processing and presentation of peptides to CD8+ and CD4+ T cells 
respectively. Variations in these alleles clearly impact the immune response directly. 
However, there are many other immune related genes that map within or close to the Class I 
and Class II genes. These include complement components C4, C2 and Factor B, TNFa, 
Lymphotoxin and B as well as the transporter of peptides, TAP. All of these genes show 
some polymorphism and murine gene knockouts show robust phenotypes raising the 
possibility that they could contribute to the involvement of the MHC and immune 
phenotypes.
1.2 Genome-Wide Associations with Immune Tolerance
The discovery that single nucleotide polymorphisms (SNP) are common throughout the 
genome, coupled with the ability to perform detailed interrogation of many individuals using 
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microarray based technology opened a new frontier. Many polymorphisms could be tested 
simultaneously and correlated with disease phenotype. Over the ensuing years, many studies 
utilizing this approach have identified non-MHC candidate genes that modulate 
immunological phenotypes. Generally referred to as Genome Wide Association studies 
(GWAS), it was widely applied to large cohorts of patients and controls. Literally hundreds 
of disease phenotypes have been examined in GWAS studies ranging from autoimmune 
diseases like Type 1 Diabetes, Multiple Sclerosis, and psoriasis, to immunologically related 
birth defects [15]. A major limitation to optimal utilization of GWAS data is statistical and 
computational. When many traits (tens of thousands) are interrogated, false positive 
associations are common and statistical correction becomes challenging. A second limitation 
in this approach is that most SNPs do not occur in protein coding regions, and thus it 
difficult to directly infer function. SNPs in noncoding regions potentially regulate 
transcription by altering enhancers or promoters, but direct linkage to function is difficult 
given sequence variant data alone. Thus SNPs may allow associations of a phenotype with a 
region of the genome, but not with a specific gene. This is formally equivalent to the 
statistical analysis of Quantitative trait loci, where well-developed mathematical approaches 
were both applied directly and further developed. Additional limitations of GWAS include 
its weakness at rare variant discovery [16], continued issues with “missing heritability” [17], 
and the presences of ascertainment biases that lead to overestimation of the effect size 
during the initial discovery of an association in under-powered GWA studies, termed the 
“winner' curse” [18]. These and other characteristics of GWAS have led the field to increase 
the size of the cohorts to enormous numbers. Since the initial GWAS in 2005 the samples 
sizes have grown from 146 to over 339,000 individuals [19,20]. An interesting analysis of 
GWAS, focusing on the immune system [21], catalogs many of the discussions about the 
utility of GWAS and its limitations.
Nonetheless, GWAS has become a powerful tool for the discovery of genes that contribute 
to heritable disease phenotypes in monogenic and polygenic diseases. Rheumatoid Arthritis, 
Type I Diabetes, Lupus, celiac disease, Chrohn's disease, Multiple Sclerosis, Behcet's 
disease, Vitiligo, ankylosing spondylitis, psoriasis, Graves disease, eczma and other atopic 
allergic diseases, Wegener's, Sjogren's, and ANCA-associated vasculitis have all been 
investigated in large productive GWAS studies [22]. Association studies have also identified 
immune system contributions to unexpected diseases, most notably schizophrenia [23]. 
These studies have extended our understanding of the immune system, however GWAS 
studies have been less successful in elucidating genetic contributions of the adaptive 
immune system genes that undergo V(D)J recombination, class switch recombination and 
somatic hyper-mutation (TCR alpha, beta, gamma, delta, Ig Heavy and light chains) due 
their extreme non-germline modifications. The extended Major Histocompatibility Complex 
(MHC) locus has been identified as a disease-contributing locus in a large number (over 
200) of GWAS studies [15], whereas only a limited number of studies have mapped the 
genetic contributions of the adaptive immune loci (TCR and Ig) to disease phenotypes. The 
sleep disorder Narcolepsy, Trypanosoma cruzi cardiomyopathy, poor Renal transplant 
outcome (TRAV19/20), and Intraoccular pressure (TRAJ17) have been associated with the 
TCR alpha extended locus [24-27]. The Ig heavy chain locus has been genetically associated 
with Kawasaki's disease, Alzheimer's, and Multiple Myeloma [28-30]. There is an 
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imbalance in the number of associations between the TCR and the MHC loci, the very genes 
whose products present peptide antigens to those of the TCR loci. This imbalance suggests 
that GWAS fails to identify the contributions of TCR genes to relevant disease processes.
1.3 iWAS: immunome Wide Association Study
The non-germline nature of V(D)J recombination, at the TCR/Ig loci, necessitates a novel 
experimental and statistical approach. Using high throughput immune receptor sequencing 
to identify “biomarkers” of the adaptive immune system we developed the immunome Wide 
Association Study (iWAS) to compensate for the weakness of GWAS studies when 
investigating adaptive immune receptor repertoire characteristics. The iWAS tool should be 
able to identify the differential characteristic of the Ig and T cell receptor repertoire that 
correlate with stratified immunological outcomes, like characterizing the repertoire 
differences between unsuccessful and protective vaccination outcomes [31].
However, most relevant to Ray Owen's work on tolerance, iWAS could be used for 
identifying the repertoire differences between pre-selection and post-selection thymic TCR 
repertoire (DN1 vs single positive thymic populations). While measurement of SNPs 
allowed the development of GWAS analysis, until recently there was no comparable method 
to interrogate the adaptive immune system receptor sequences. The great challenge for 
developing an immunome Wide Association Study (iWAS) is that the targeting receptors (T 
cell Receptors and Antibodies) used by lymphocytes to confer antigen specificity of the 
immune response are only partially germline encoded. During lymphocyte development, 
each lymphocyte has the potential to generate a unique immune receptor.through enzymatic 
rearrangement of Variable (V), Diversity (D), and Joining (J) germline gene segments 
(TCRβ, TCRδ, and Ig heavy chain) or V and J germline gene segments (TCRα, TCRγ, Ig 
light chain). A variable number of germline nucleotides may be removed and non-germline 
encoded nucleotides added at each of the recombination junctions. These non-templated 
additions are created stochastically by both nucleases and polymerases in each lymphocyte 
and as such can not be mapped using the SNP analysis performed in classical GWAS. Thus 
the extent of variation of the immune receptors that the adaptive immune system depends on 
for its function cannot be captured, which represents the most significant limitation to using 
GWAS analysis to study the role of the adaptive immune system in immunological 
phenotypes. The magnitude of diversity of the immune receptor repertoire also poses a 
significant impediment to analysis, in that the potential repertoire is estimated to be between 
1015 and 1018 unique receptors. While there are only about 1011 immune cells in a human, 
this still represents a significant increase in data complexity over classical SNP analysis 
which typically relies on 105-106 SNPs [32].
Before Next Generation Sequencing (NGS), it was impossible to determine the impact of the 
adaptive immune receptor repertoire on the subsequent immune response because the prior 
techniques provided insufficient sampling of the repertoire. DNA sequencing of immune 
receptors TCR and antibodies previously required cloning and sequencing each immune cell 
receptor one by one. It was a great effort and cost to obtain even a few hundred sequences. 
This was far too few to effectively interrogate the breadth of an immune repertoire. Thus, 
sequence analysis was largely confined to examining the antigen specific response with the 
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idea of better understanding the biochemical interaction of immune receptors and their 
targets. There have been many past efforts to define sequence motifs that correlate with the 
ability of a specific T cell to respond to a particular epitope. These were traditionally defined 
by examining the TCR sequences of a set of antigen specific T cell clones and defining 
motifs among the TCR expressed by the distinct clones. This analysis was done by visual 
inspection and was performed by first asking if the Vb or Jb gene usage itself was skewed, 
then picking the most frequent Vb and aligning the CDR3 regions for the highest sequence 
similarity and determining visually if a consensus is created from the set of alignments. The 
establishment of a consensus motif allowed the examination of datasets derived from 
unselected cells for the presence of those sequences and their relative clone frequencies. 
This type of analysis was narrow in scope and, by necessity, ignored the contribution of the 
remaining repertoire of immune receptors. In addition, the requirement that sequences with a 
similar phenotype have a similar primary sequence motif is unreasonable in polyclonal 
responses in the setting of high polymorphism at the MHC and other loci. The advent of 
Next Generation Sequencing (NGS) has both increased the throughput of sequencing and 
decreased the cost more than five orders of magnitude in the last ten years. This comes 
purely as a result of technical improvements and the ability to parallelize the biochemistry 
and data acquisition. NGS techniques have been adapted from genomics and RNAseq 
applications to immunomics by focusing the sequencing efforts on the immune receptor's 
VDJ recombination junction. A number of basic science and commercial groups have 
developed assays for sequencing TCR/BCR repertoire utilizing NGS instruments (e.g. 
Illumina, Roche 454, Ion Torrent) and have coined multiple names for the technique 
including Repertoire-Seq, Rep-Seq, innunoSEQ, iR-Profile, ClonoSeq, T-cell 
metagenomics, LymphoSIGHT, etc [33-37]. The field has progressed sufficiently so that we 
are capable of sequencing tens of millions of immune receptors from hundreds of 
individuals; hence we can now comprehensively evaluate the extent and breadth of the 
adaptive immune system.
The throughput of sequencing immune receptor is now sufficient to replace the markers used 
in the classical association studies (SNP's) with markers that will reflect the actual diversity 
of the adaptive immune response, the immune receptor sequences (TCR and antibodies). 
While the field of informatics has also greatly improved, it lags significantly behind the 
biochemistry of high throughput sequencing. Current analyses have described the extent of 
clonal diversity in healthy repertoires and in some cases correlated repertoire diversity 
measures to clinical outcomes [31,38], however detailed analyses of population sequence-
level characteristics to immunologic or clinical phenotypes have not been done. Informatics 
to assess the contribution of the adaptive immune system to immune phenotypes is virtually 
non-existent, necessitating the development of the iWAS pipeline.
2. Material and Methods
In principle, the concept of the GWAS and the iWAS is the same. There are an array of 
features or markers (TCR/Ig sequences and/or TCR/Ig sequence characteristics; analogous 
to the SNPs used in a GWAS), which are measured in each immune receptor for each 
individual within two populations (e.g. control and effected). These populations could 
represent patients who are either well (outcome 1) or unwell (not outcome 1), or the 
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populations could represent those who exhibit differential biological characteristics (e.g. 
good vaccine responders vs. poor vaccine responders), or the repertoire sequences 
themselves can be grouped by intrinsic classifiers (e.g. sequences shared by multiple 
individuals vs. those unique to one individual). iWAS provides a method by which adaptive 
immune receptor repertoire features can be associated with outcome/biological group with 
the opportunity to perform robust statistical significance testing.
While there are many statistical methods to test for associations between quantitative 
predictive markers and a trait or a biological characteristic of interest, the nature of the 
marker variables measured often impacts the choice of statistical methods chosen for 
determining an association. The choice of statistical tool often depends on whether the 
outcome trait variable is continuous or categorical and it also depends on the complexity and 
size of the datasets (e.g. if there are a large number of parameters relative to the number of 
individuals in the dataset, the so-called large p, small n problem, as in a classical GWAS 
analysis). In this manifestation of an association study, we tailored the initial embodiment of 
the iWAS to focus on a binary outcome question, where we desired to identify the predictor 
variables that most contribute to the variance of the binary outcome (e.g. TCR sharing, 
described below). We chose to develop an association method that relied upon penalized 
logistic regression (PLR) where we performed a joint analysis as opposed to a marginal 
analysis on each predictor variable (as is typically performed in a GWAS). iWAS utilizes 
shrinkage techniques for culling predictors with minimal to no predictive effects in the 
model. Briefly, the iWAS analysis minimizes a penalized logistic log-likelihood function to 
identify a comprehensive set of TCR characteristics (the predictors X = (X1, …, Xp)) which 
are associated with the prediction of the response variable Y (e.g. a binary outcome 
phenotype like shared .vs. unshared). iWAS applies a shrinkage penalty for the selection of a 
subset of TCR characteristics X containing the most predictive covariates of Y. Penalties are 
imposed on regression coefficients in order to simultaneously conduct regression model 
estimation and variable selection [39-43]. The TCR features with nonzero regression 
coefficients are those features that are the most predictive of the binary response variable Y. 
iWAS utilizes the adaptive elastic net which includes the adaptive LASSO as a special case 
[40,43]. Specifically: Let Y denote the binary phenotype as Y = 1 or Y = 0 (e.g. shared and 
unshared in this test case). The data are (Xi, Yi) for i = 1, …, n, where n is the sample size 
(number of TCR sequences). Each Xi is a vector of p features (e.g. V/J gene usage, Artemis 
activity exonuclease activity at each terminus, palindromic nucleotides, n-nucleotide 
addition, etc). Thus, the design matrix X is n × p. We consider the logistic model 
 where β = (β1, … βp)′. We define p(x; β0, β) = P(Y = 1|X = 
x). The log-likelihood function is then 
. To identify important 
features and estimate their regression coefficients, we minimize the penalized log likelihood 
subject to the adaptive elastic net penalty 
where λ1, λ2>0 are the regularization parameters, and the penalty function is employed to 
shrink small coefficients for “unimportant” (non-predictive) TCR characteristics to exactly 
zero. To implement PLR with adaptive elastic net penalties, we need to select proper values 
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for the weights wj and the regularization parameters λ1 and λ2, and to select a single 
regularization parameter λ1 for our base algorithm the adaptive LASSO. The weights wj are 
data dependent and iWAS will utilize the standard maximum likelihood estimates (MLE) for 
our application to construct the weights [42]. Following the method of Friedman, Hastie, 
and Tibshirani [44], we construct a sequence of K values of λ ∈ [λmin + λmin,] on a log scale. 
A minimization solution for each value of λ1 is computed and some tuning criteria are 
applied to select the best tuning parameter. We utilize two approaches to tuning λ1, Bayesian 
Information Criterion (BIC) [45,46] and k-fold cross-validation. Minimization of the 
penalized log likelihood requires iterative numerical approximation, and iWAS will utilize 
Gradient Descent (GC) or Coordinate Descent (CD) to accomplish this task for large 
datasets, as a result of the parallelizable nature of those algorithms [47,48]. Minimization 
proceeds until convergence. The iWAS PLR-based algorithm for repertoire signature 
identification assesses the contribution of key features in predicting outcome (biological 
group membership). In an alternative embodiment of the iWAS analysis, the regression can 
be performed as a marginal analysis by regressing on each TCR/Ig marker individually, as in 
a classical GWAS.
3. Results: iWAS Test Case: Preparing to Map the Tolerant T Cell Receptor 
Repertoire
Utilizing iWAS, we have evaluated the TCR sequence determinants of publicity (TCR 
sequence sharing among multiple individuals), a long-standing conundrum in basic 
immunology. TCR sequences recovered from the peripheral circulation from multiple 
individuals, especially those with disparate MHC haplotypes, would constitute a group of 
TCR's that are more readily synthesized by the thymus and more likely capable of traversing 
the rigors of positive and negative thymic selection as well as persisting through peripheral 
tolerance mechanisms. Since the size of the potential TCR repertoire is orders of magnitude 
larger that the actual TCR repertoire in any individual, researchers initially expected that in 
V(D)J recombination, a process that was assumed to have a stochastic nature, there would 
be a small likelihood that any two individuals would produce the same “public” TCR (i.e. 
share a clonotype). However, it is clear that shared clonotypes are common features of TCR 
repertoires, not rare exceptions. Multiple theories have been developed as an attempt to 
explain the appearance of shared TCR clones. These theories include the Convergent 
Recombination Hypothesis (where the likelihood of sequence sharing is proportional to the 
number of unique VDJ recombinations that could theoretically create a given sequence), the 
Conformational Hypothesis (where the shape of the peptide presented to the TCR is 
postulated to drive the selection of shared TCRs), and the Enzyme Proxy Hypothesis (where 
the likelihood of sequence sharing is related to the regulation and bias of the V(D)J enzymes 
Rag, Artemis, TdT, etc; which generate the TCR/Ig sequence) [49]. While the 
conformational model has lost traction, the other two models (CRH and EPH models) have 
been hypothesized as the cause of TCR sharing in multiple manuscripts [50,51]. However, 
the relative contribution of these models to the TCR sharing phenomenon has not been 
tested systematically. One challenge in testing the relative contributions of these models is 
the computational complexity of modelling all possible VDJ recombinations possible to 
make each TCR (recombination “paths”) from a repertoire of biologically relevant size. A 
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second challenge is the statistical analysis of relative contribution of sequence sharing 
between the number of recombination paths and other sequence features. We investigated 
the Convergent Recombination Hypothesis to explain sharing of TCR sequences in 
C57BL/6 mice. One major prediction of the Convergent Recombination Hypothesis is that 
the frequency of appearance in vivo should be proportional to the number of recombination 
paths. We evaluated > 100,000 peripheral TCR-beta sequences derived from two un-
manipulated C57BL/6J mice by Roche 454 next generation sequencing [52] and > 3.34 
million double positive thymic TCR-beta sequences from 3 un-manipulated C57BL/6J mice 
by Illumina HiSeq next generation sequencing [53] (NCBI SRA Accession # SRA026496). 
We then devised an in silico model to calculate the number of recombination paths, for each 
TCR observed in vivo, using a novel GPU parallel processing approach, which interrogated 
the theoretical TCR repertoire at greater than 1014 different recombination paths [52]. We 
then compared the observed in vivo frequency with the recombination path number. As 
demonstrated in our prior work (Streimer at al), the recombination paths do not correlate 
well with high in vivo frequency [52]. Thus, one prediction of the CR hypothesis is not 
supported by this analysis. A second prediction of the Convergent Recombination 
Hypothesis is that the public sequences that are shared between individuals would be those 
that are “easier to make”, that is they have more theoretical ways to make them (e.i. higher 
recombination paths). The Enzyme Proxy Hypothesis however, predicts that the public TCR 
sequences will differ in the extent of activity of V(D)J enzymes (e.g.Rag, Artemis, TdT), 
which are quantifiable from the TCR sequences. The recombination path number and the 
enzyme characteristics are readily representable as TCR features in the iWAS analysis. 
Using the iWAS method, we analyzed the TCR sequence features and recombination path 
numbers for enrichment in the shared sequences. As shown in Figure 1, the TCR 
characteristics that represent the V(D)J recombination enzyme activities yielded non-zero 
logistic regression coefficients (beta) indicating that those enzyme features contain 
predictive information about the binary response variable for TCR “publicity” (TCR 
sharing) in this model. Strikingly, the regression coefficient yielded for the recombination 
path enumeration was a zero coefficient value indicating that the recombination paths (“the 
number of ways each TCR can theoretically be made”) for each TCR is not predictive of 
TCR sharing. The results in Figure #1 A and B, are shown for the two completely 
independent mouse experiments, performed on different tissue (thymic and peripheral T 
cells), in different laboratories, and sequenced on different platforms (454 vs Illumina). 
These results support the Enzyme Proxy Hypothesis, whereby a decreased activity 
(indicated by the negative beta coefficient values) of the V(D)J enzymes appear to correlate 
with TCR sharing. This suggests that the enzyme proxy model is perhaps is a better fit to the 
repertoire data than is the convergent recombination model and the results also suggest that 
the iWAS algorithm is capable of identifying TCR characteristics that correlate with 
biological outcomes. When the recombination path counting algorithm was restricted to 
calculate the recombination paths allowed during the condition of zero n-nucleotide 
addition, a small regression coefficient was obtained, indicating that the convergent 
recombination hypothesis may be contributory for cases where no n-nucleotides are added at 
the V(D)J gene junctions (data not shown). In a traditional GWAS study there is what is 
termed the “large p, small n” problem where the number of predictor parameter (p) is 
represented by each SNP and the number of individuals (n) in the study is represented by the 
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number of patients in the affected group and the number of healthy donors in the control 
group (i.e. the number of individuals in the response variable). Normally the number (p) 
predictor parameters (SNPs) is very large and the number of individuals in the binary 
response variable groups is much smaller (n); leading to false positive errors (Type I) due to 
the large number of comparisons that are performed. To compensate, GWAS studies often 
control for this false discovery (Bonferroni) which then leads to false negative errors (Type 
II) which leads to missed associations [54]. Penalized regression analysis have been used in 
advanced GWAS studies to balance the Type I and II errors [55], and we have adopted this 
approach in the iWAS in preparation for clinically based iWAS studies which would also be 
subject to the “large P, small n” problem. However, in this test case the powering of number 
of individuals (n) in the two arms of the association study is based on binning the TCR 
sequences into (1) Shared and (2) Unshared groups not based on the number of individual 
donors in the trial. While calculations to determine the level of powering for a study of this 
kind will have to await evaluations for the strength of association of immunological 
phenotypes, the powering in the 3-mouse dataset exceeds 3 million which is currently 10 
fold higher than the largest GWAS performed to date [20]. As such, the test case within this 
study is likely to be sufficiently powered. Nevertheless, we are currently evaluating both 
convergent recombination and enzyme proxy models that potentially explain TCR sharing 
using larger data sets (powered with more individuals and greater sequencing depth per 
individual) of both murine and human TCR-beta sequences.
4. Discussion: How can iWAS be used?
The major strength of GWAS studies is that many genetic loc can be simultaneously 
interrogated. Similarly, the major strength of an iWAS is the ability to evaluate very large 
numbers of immune receptors and meta-data parameters (clinical, biological, or 
experimental) in parallel While in the past only a small number of parameters could be 
addressed at once, now with the combination of very large numbers of sequences and 
sequence features, more power is added to evaluate traits that depend on adaptive immunity. 
The features that can be used can vary, but include not only the sequences themselves, but 
the length of the CD3 region, its composition, the length of the nontemplated regions, as 
well as the V and J gene usage.
4.1 What can be examined using the iWAS approach?
iWAS and Infection/Vaccination—The clear choice for utilizing iWAS will be in the 
investigation of diseases liked to immunity. These include infectious diseases such as B- and 
T-cell responses to influenza, West Nile Virus, HIV and Hepatitis C (along with other 
infectious diseases), as well as vaccination responses. In the example of Hepatitis C, it will 
be important to stratify the patients by their outcomes; those who clear virus without 
treatment, those that require treatment and finally those who go on to develop cirrhosis and 
ultimately hepatocellular carcinoma. Identification of the T cell receptor features associated 
with effective immunity could allow clinicians to predict the outcomes of disease early in 
the disease course, and tailor treatments appropriately. In addition, the identification of 
Ig/TCR repertoire features that associate with protective or unsuccessful vaccination 
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responses may aid in the development of novel vaccine approaches or adjuvant optimization 
strategies.
iWAS and Autoimmunity—Autoimmune disorders may also be amenable to iWAS 
analysis. Candidates with well-defined targets and strong HLA association such as Type 1 
diabetes, ankylosing spondylitis, narcolepsy, and psoriasis are optimal analytical targets. In 
addition, antibody mediated diseases like Hashimoto's thyroiditis and Myasthenia Gravis 
can have both B and T cell repertoire interrogated. T cell repertoires may be important even 
for antibody mediated diseases, where T cell help is required for the B cell responses, and in 
some cases T cells also likely contribute to the disease process. The examination need not be 
limited to the antigen specific repertoire. iWAS allows users to expand their examinations to 
evaluate the naïve repertoire of longitudinal samples. Another disease where iWAS would 
be of value would be in children who contracted severe RSV infections early in life and who 
have a very high relative risk of later developing asthma. This could potentially stratify the 
risk of developing severe asthma from those children who will remain non-asthmatic. It will 
also be important to evaluate if iWAS analysis would be informative for analyzing patients 
whose disease pathology has a less clear-cut immune etiology in the clinical setting, as in 
Lyme disease and coccidiomycosis.
iWAS and Transplantation—Transplantation-associated outcomes are particularly 
relevant, as iWAS may be leveraged to identify differential outcomes both in solid and 
liquid tumors. The specific clinical applications include, but are not limited to, evaluating 
the extent of irradiation during immune-ablation, judging post-transplant 
immunosuppression regimen, monitoring infectious sequela (e.g. CMV reactivation, 
bacterial sepsis, etc), screening for rejection and graft-vs-host disease, and examining stem 
cell reconstitution (allogeneic or autologous) [56].
iWAS and Cancer—Cancer represents an important target as well. Many tumors are 
immunogenic, and alteration of the immune responses by cytokine interventions or immune 
checkpoint inhibition (modulation of PD-1 and/or CTLA4) have been useful in multiple 
tumor types [57]. In some of those cancers, responses that are inhibited by regulatory T-cells 
(Treg) would be important to evaluate both the effector population (to identify potential 
candidates for T-cell therapies) as well as the regulatory population. iWAS offers the ability 
to evaluate this area of immuno-cancer surveillance by analyzing the characteristics of the 
adaptive immune response to tumors that predict successful response or resistance to 
immunotherapy.
Lympoid tumors (lymphoma, leukemia, and myeloma) are cancers of adaptive immune cells 
and are an important special case. Not only can lymphoid tumors themselves be 
immunogenic and thus targeted by the remaining adaptive immune system (hence leveraged 
for potential immunotherapy just like solid tumors), but lymphoid tumors also harbor the 
unique V(D)J recombinant receptor that can serve as a truly unique tumor marker. Both T 
and B cell derived tumors will express a unique immune receptor that can be readily 
monitored by high throughput sequencing techniques. The sensitivity of detection by 
sequencing is many times higher than conventional cytopathology and so minimal residual 
disease can be detected, even in the presence of large numbers of normal lymphocytes.
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5. Conclusion: How does this fit with Ray Owen and tolerance?
Ray was always a fan of new technology. He embraced protein sequencing and was a big 
supporter of mathematical analysis of complex data, no doubt stemming from his own 
background as an agricultural geneticist. The greatest excitement from the iWAS is not 
merely that we can identify biomarkers of immunological processes, like the development of 
tolerance, but that these immune biomarkers immediately suggest a way to test mechanism 
of biological processes. Thus, at the dawn of the era of immuno-genetics and immuno-
informatics of the adaptive immune system, investigators now have new tools to suggest 
how an important immunological phenotype can be related to function and then how it can 
be manipulated.
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Highlights
• Adaptive Immune Receptors (Ig/TCR) Genetics rarely assessed in Genome 
Wide Association Studies
• immunome Wide Association Studies (iWAS) of Ig/TCR data can reveal 
immune genetic contributions
• iWAS shows Enzyme Proxy Model correlates with TCR sharing
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Figure 1. TCR Sharing: iWAS Regression Coefficients
The recombination path numbers resulted in a zero regression coefficient (beta), however 
the enzyme correlates of the TCR characteristics yielded non-zero coefficients in both 
datasets. A)2 mouse dataset of CD8+ peripheral T cells sequenced with a Roche 454 
instrument, B)3 mouse dataset of double positive (CD4+CD8+) thymocytes sequenced with 
an Illumina Hiseq2000 instrument (NCBI SRA Accession # SRA026496). The solid line 
above the graph indicates the predictor variables related to the enzyme correlates, whereas 
the dotted line indicates the convergent recombination path variable.
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